ReviewOncoimmunology
CEACAM1 as a multi-purpose target for cancer immunotherapy.
Matthew Dankner et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
88 papers cite itlatest 60 shown
trialcites it
ReviewOncoimmunology
Matthew Dankner et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.